Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC).Methods: Data from trials comparing EG...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Chee Khoon Lee, Lucy Davies, Yi Long Wu, Tetsuya Mitsudomi, Akira Inoue, Rafael Rosell, Caicun Zhou, Kazuhiko Nakagawa, Sumitra Thongprasert, Masahiro Fukuoka, Sally Lord, Ian Marschner, Yu Kang Tu, Richard J. Gralla, Val Gebski, Tony Mok, James Chih Hsin Yang
التنسيق:	دورية
منشور في:	2018
الموضوعات:	Biochemistry, Genetics and Molecular Biology Medicine
الوصول للمادة أونلاين:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027265241&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56757
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
المؤسسة:	Chiang Mai University

مواد مشابهة

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
بواسطة: Chee Khoon Lee, وآخرون
منشور في: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
بواسطة: Lee C., وآخرون
منشور في: (2017)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
بواسطة: Wong, A.S., وآخرون
منشور في: (2014)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
بواسطة: Wang D.D., وآخرون
منشور في: (2019)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
بواسطة: Ma, L, وآخرون
منشور في: (2020)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
بواسطة: Afrita Amalia Laitupa, -, وآخرون
منشور في: (2019)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
بواسطة: Wong, A.S., وآخرون
منشور في: (2014)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
بواسطة: Natthaporn Sueangoen, وآخرون
منشور في: (2020)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
بواسطة: Masahiro Fukuoka, وآخرون
منشور في: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
بواسطة: Tony Mok, وآخرون
منشور في: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
بواسطة: Tony Mok, وآخرون
منشور في: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
بواسطة: Tony S. Mok, وآخرون
منشور في: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
بواسطة: Tony S. Mok, وآخرون
منشور في: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
بواسطة: Chee Khoon Lee, وآخرون
منشور في: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
بواسطة: Chee Khoon Lee, وآخرون
منشور في: (2018)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
بواسطة: Yeo, W.-L., وآخرون
منشور في: (2011)

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
بواسطة: Voon, P.J., وآخرون
منشور في: (2014)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
بواسطة: Fukuoka M., وآخرون
منشور في: (2017)

Editorial: Update on Anti-EGFR therapy
بواسطة: Daniel Chua, وآخرون
منشور في: (2018)

Editorial: Update on Anti-EGFR therapy
بواسطة: Daniel Chua, وآخرون
منشور في: (2018)

PERBANDINGAN RESPONS TERAPI GEFITINIB PADA PASIEN KPKBSK DENGAN EGFR MUTASI EXON 19 DAN EXON 21
بواسطة: Titin Sholihah Agustina, NIM011180901
منشور في: (2017)

PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS DR SOETOMO SURABAYA
بواسطة: Afrita Amalia Laitupa
منشور في: (2019)

Erlotinib in previously treated non-small-cell lung cancer
بواسطة: Frances A. Shepherd, وآخرون
منشور في: (2018)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
بواسطة: Assiddiq, B.F., وآخرون
منشور في: (2014)

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
بواسطة: Giorgio V. Scagliotti, وآخرون
منشور في: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
بواسطة: Wu Y., وآخرون
منشور في: (2017)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
بواسطة: Reungwetwattana T.
منشور في: (2023)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Lung cancer working group report
بواسطة: Nagahiro Saijo, وآخرون
منشور في: (2018)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
بواسطة: Cho B.C.
منشور في: (2023)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
بواسطة: Suresh S. Ramalingam, وآخرون
منشور في: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
بواسطة: Suresh S. Ramalingam, وآخرون
منشور في: (2020)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
بواسطة: Chaichana Chantharakhit
منشور في: (2019)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
بواسطة: Scagliotti G.V., وآخرون
منشور في: (2014)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
بواسطة: Auliya Hafizah, Raysa

Serum concentrations of erlotinib at a dose of 25 mg daily
بواسطة: Costa, D.B., وآخرون
منشور في: (2014)